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Available online 10 March 2016Background:Multimorbidity in heart failure (HF), deﬁned asHF of any aetiology andmultiple concurrent conditions
that require active management, represents an emerging problem within the ageing HF patient population world-
wide.
Methods: To inform this position paper, we performed: 1) an initial review of the literature identifying the tenmost
common conditions, other than hypertension and ischaemic heart disease, complicating the management of HF
(anaemia, arrhythmias, cognitive dysfunction, depression, diabetes, musculoskeletal disorders, renal dysfunction,
respiratory disease, sleep disorders and thyroid disease) and then 2) a review of the published literature describing
the association betweenHFwith each of the ten conditions. From these datawe describe a clinical framework, com-
prising ﬁve key steps, to potentially improve historically poor health outcomes in this patient population.
Results:We identiﬁed ﬁve key steps (ARISE-HF) that could potentially improve clinical outcomes if applied in a
systematic manner: 1) Acknowledge multimorbidity as a clinical syndrome that is associated with poor health
outcomes, 2) Routinely proﬁle (using a standardised protocol — adapted to the local health care system) all pa-
tients hospitalised with HF to determine the extent of concurrent multimorbidity, 3) Identify individualised pri-
orities and person-centred goals based on the extent and nature of multimorbidity, 4) Support individualised,
home-based, multidisciplinary, case management to supplement standard HF management, and 5) Evaluate
health outcomes well beyond acute hospitalisation and encompass all-cause events and a person-centred per-
spective in affected individuals.
Conclusions:Wepropose ARISE-HF as a framework for improving typically poor health outcomes in those affect-
ed by multimorbidity in HF.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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is challenging health care systems worldwide. For example, almost half
of all US adults live with one chronic illness [1] andmultimorbidity is in-
creasing as the population ages [2]. Accordingly, recent estimates suggest
that two-thirds of US Medicare beneﬁciaries (close to 21 million pa-
tients) have two or more chronic conditions and more than one-third
have four or more [3,4]. Similarly, in Australia and Europe, a quarter of
the population has multimorbidity, with prevalence and complexity in-
creasing with age: 83%, 58% and 33% of patients aged 75 years or older
have at least two, three or four concurrent conditions, respectively, re-
quiring active management [5,6]. Unsurprisingly, multimorbidity is not
a benign phenomenon. The risk of hospitalisation, re-hospitalisation,
and death rise as the number of chronic conditions increases [7].
Multimorbidity is common in patients with heart failure (HF), in-
creasing their risk for poor health outcomes. Lone HF is rare and is ex-
ceedingly rare in the predominant HF patient population aged 75 years
and older [8]. In the US, approximately 40% of Medicare beneﬁciaries
with HF have N5 non-cardiac conditions and this group accounts for
N80% of the total inpatient HF-related hospital days in the US [9]. Annual
total costs for HF are expected to more than double between 2012 and
2030 ($31 billion to $70 billion USD) [10] making HF the foremost con-
tributor to Medicare expenditures [11]. The majority (61%) of hospital
readmissions are attributable to multimorbidity [12], and occur within
15-days of discharge [13]. About half of all hospitalisations in HF patients
are thought to be preventable [9]. This is particularly problematic in
those with HF and preserved ejection fraction, for whommultimorbidity
is the major driver of hospitalisations. To date, authors of expert guide-
lines have struggled to address the issue of multimorbidity in HF and ar-
ticulate clear pathways to optimise health outcomes. Not surprisingly,
however, there has been increasing interest in providing clinicians and
health care teams with more guidance to improve the management of
HF in the context of multimorbidity [14].
2. Aims
We recognise the complex clinical challenges inherent to managing
HF in the setting ofmultimorbidity and the limitations of practice guide-
lines in providing a comprehensive overview of the applicability of
treatment options. Thus, the speciﬁc aims of this position paper (from
an international, multidisciplinary panel of health professionals with
an ongoing interest and expertise in HF management) are two-fold:
1. To provide a comprehensive overview of the current literature focus-
sing on themost common conditions requiring concurrent treatment
and management in patients with HF.
2. To articulate a practical framework for establishing a systematic re-
sponse to this increasingly common clinical phenomenon that has
the potential to improve health outcomes.
We explicitly recognise that the practical steps outlined in this doc-
ument are yet to be proven in terms of improved health outcomes (in-
deed they form the basis for a proposed, international, multicentre
trial). However, we propose that these steps be used (in part or in
their entirety) to inform and complement contemporary guidelines to
improve health outcomes in those affected by HF and multimorbidity,
regardless of the health care system in which they are managed.
3. Literature review
We began by surveying the literature, noting a contemporary study
of multimorbidity in the HF patient population [15,16]; we identiﬁed
the ten most prevalent concurrent conditions in HF (other than hyper-
tension and ischaemic heart disease) requiring concurrent manage-
ment. The ten most prevalent conditions (other coronary disease and
hypertension) identiﬁed in the literature were anaemia, sleepdisordered breathing, respiratory disease, Type 2 diabetes, depression,
renal impairment, cognitive impairment, musculoskeletal disorders, ar-
rhythmias, and thyroid disease. This list was then validated in two large
patient cohorts (N1000 patients) in Australia and the USA via purpose-
ful proﬁling (comprising detailed psychosocial and clinical phenotyp-
ing) of typically older patients with HF at the time of hospital
discharge.Whilstwe acknowledge thismay not represent the deﬁnitive
“top ten” list of concurrent conditions in HF (indeed we considered a
number of other potential conditions of interest) in all settings, we
largely focus on our validated list. These conditions are often closely
linked, occur concomitantly, and represent natural targets for better
management from amultimorbidity perspective due to the typical clin-
ical “conundrum” they represent — see Fig. 1: A conundrum of
multimorbidity in HF (reproduced with permission) [15]. As depicted
in Fig. 1, the patterns of interaction inmultimorbidity present an oppor-
tunity to prospectivelymanage predictable gaps in patient care, such as
polypharmacy, care coordination, and communication amongmultidis-
ciplinary providers.
Focussing on these ten pre-speciﬁed conditions, we then searched
the literature (using the speciﬁc search terms outlined in Table 1) to
identify publications focused on the management of these conditions
in the setting of HF. Speciﬁcally, the search was performed using
Medline and was limited to reports published during the period 2005
to 2015, in order to capture the most up-to-date literature. Ten individ-
ual searcheswere conducted inwhich the speciﬁc co-morbidity of inter-
est, along with HF, and their combined management or treatment was
entered into Medline. This yielded a total of 3573 citations, which
were then reviewed for relevancy — see Table 1. The full text articles
were reviewed and a tabulated summary of extracted information
from 194 papers is provided in Supplementary Table 1.
The literature reviewed using this search strategy and subsequent
data extraction (noting the often fragmented approach to examining
multimorbid conditions in HF) was contextualised according to the au-
thors' own experiences in managing large numbers of older patients
(i.e. those aged 75 years or more) with HF and multimorbidity. A prag-
matic clinical framework, ARISE-HF, (comprising a series of ﬁve key
steps— see text box below) to frame clinical practice, research, and fu-
ture health policy was initially drafted by SS and BR and subsequently
circulated for review, revision and approval by the group.
The section below expands upon the ARISE-HF framework and how
it might be applied on a systematic basis.
4. A step-wise approach to improve health outcomes (ARISE-HF)
4.1. Step 1: Acknowledge multimorbidity as a clinical syndrome associated
with poor health outcomes
As previously noted by Tinneti and colleagues [17], multimorbidity
in HF has emerged as a clinical syndrome associated with poor health
outcomes. Based on our reviewof the literature (see below), it is reason-
able to classify HFwith concomitantmultimorbidity as a distinct clinical
syndrome in order to provoke a more systematic response from the
health care system. For example, it is of particular concern that HF
Fig. 1. A conundrum of multimorbidity in HF (reproduced with permission).
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areas are at increased risk for all-cause re-hospitalisation, suggesting
that illness burden may inﬂuence the association between income andTable 1
Search terms used to identify published reports focussing on HF and the ten pre-speciﬁed
concurrent conditions with total citations found.
Comorbidity Search terms Citations
Anaemia Anaemia OR anemia 303
AND heart failure
AND Management OR treatment
Sleep disordered
breathing
Sleep disordered breathing OR obstructive sleep
apnoea OR central sleep apnoea
179
AND heart failure
AND management OR treatment
Respiratory
disease
Respiratory disease OR dyspnoea OR chronic
obstructive pulmonary disease
817
AND heart failure
AND management OR treatment
Diabetes mellitus Diabetes mellitus 486
AND heart failure
AND management OR treatment
Depression Depression 387
AND heart failure
AND management OR treatment
Renal
impairment
Renal impairment OR renal dysfunction 322
AND heart failure
AND management OR treatment
Cognitive
impairment
Cognitive impairment 74
AND heart failure
AND management OR treatment
Musculoskeletal
disorders
Musculoskeletal disorders OR osteoporosis OR
osteopenia OR osteoarthritis OR rheumatoid
arthritis
105
AND heart failure
AND management OR treatment
Arrhythmias Arrhythmias OR atrial ﬁbrillation 814
AND heart failure
AND management OR treatment
Thyroid disease Thyroid disease OR hyperthyroidism OR
hypothyroidism
86
AND heart failure
AND management OR treatmentoutcomes in these patients [18]. In contrast to an increasing recognition
that speciﬁc clusters of conditions are associated with extended length
of hospital stay, elevated cost, and increased risk of mortality [19], the
current literature is largely fragmented, focussing on common clinical
dyads (e.g. HF and diabetes) and framing clinical management in isola-
tion from other complicating factors (e.g. renal dysfunction). Supple-
mentary Table 1 summarises key clinical issues for each condition of
interest.4.2. Step 2: Routinely proﬁle (using a standardised protocol) patients with
HF to determine the extent of concurrent multimorbidity
A logical extension to recognising multimorbidity in HF as a clinical
syndrome requiring a coordinated clinical response is to identify
which patients (particularly those at high risk of related poor health
outcomes) are affected by what condition. As such, we recommend all
older patients admitted to hospital with HF should be systematically
proﬁled for multimorbidity in order to optimise care. At minimum,
this would include the ten common conditions identiﬁed that compli-
cate HF management (other than routinely diagnosed and managed
coronary artery disease and hypertension) with consideration of other
potential conditions according to the patients clinical proﬁle. In the
presence of multiple admissions/clinical instability, it would be reason-
able to review the extent and progression of multimorbidity on a regu-
lar basis. Findings should be noted in the clinical records and included as
part of any communication with the patient's wider health care team.
Advanced electronic health records (EHR) and informatics would facil-
itate both the identiﬁcation and tracking of such individuals. However,
EHR capacity is highly variable across different health systems. It is
also important to note that any protocol for managing patient's with
HF andmultimorbidity will likely rely on a component of “routine” pro-
ﬁling (e.g. review of prior records and standard review of electronic sys-
tems) as well as an active component of proﬁling (e.g., to determine
cognitive function). Although proﬁling focusses on hospitalised individ-
uals, there is a clear need to consider when it is best andmost reliable to
perform proﬁling; ideally when the individual is clinically stable and, in
some cases, post hospital discharge. The latter in particular requires
4 S. Stewart et al. / International Journal of Cardiology 212 (2016) 1–10clear lines of communicationwith the primary health care team. Table 2
summarises the deﬁnitions and methods that might be routinely ap-
plied to identify ten common comorbid conditions in HF (i.e. those con-
ditions of particular interest to this position paper).
4.3. Step 3: Identify individualised priorities and person-centred goals based
on the extent and nature of multimorbidity
As shown in Supplementary Table 1, there are potentially many
competing priorities arising frommultimorbidity in HF that are not eas-
ily addressed in a generic manner — hence the historical difﬁculty for
guideline committees to provide speciﬁc recommendations in the set-
ting ofmarginal beneﬁt–risk ratios. For example, there has been a reluc-
tance to prescribe high doses of neurohormonal/vasodilator therapy in
the setting of frailty and high risk of falls and/or evidence of progressive
renal dysfunction despite the potential beneﬁts [20,21]. On this basis,
we suggest a structured approach that considers the nature and severity
of multimorbidity, deﬁnes an individualised list of clinical priorities and
identiﬁes the need for specialist consultation when appropriate. Criti-
cally, as part of a patient-centred approach, patient preferences and
goals regarding their own health [22], as well as conﬂicting and contra-
indicated treatment options should play a prominent role in the deci-
sion points of the algorithm. This requires a truly multidisciplinary,
team-based approach to management [23] that provides the patient
and their caregiverswith the knowledge to foster better care and to pro-
vide advice on their options pertaining to their treatment and manage-
ment. Whilst we have suggested a clear focus on the hospitalised
patient (with the opportunity to complete most if not all components
of screening for multimorbidity), it is clear that subsequentTable 2
Suggested framework for documenting and quantifying multimorbidity in HF.
Co-morbidity Data source and determination
Anaemia Full blood examination during hospital admission
Atrial and ventricular arrhythmias Review of medical notes plus review of prescribed p
at discharge
If high clinical suspicion of undiagnosed arrhythmia
inpatient telemetry or extended ECG Holter monitor
Cognitive impairment/dementia Assessed via Montreal Cognitive Assessment (MoCA
hospital discharge by trained personnel
Depression/anxiety Assessed via PQ-2 [130] questionnaire prior to hospi
trained personnel plus review of medical notes and
pharmacotherapy at discharge. If positive, apply mo
comprehensive tool (e.g. HADS) [131]
Diabetes and metabolic disorders Review of medical notes and prescribed pharmacoth
discharge
Calculation of body mass index (BMI)
If high clinical suspicion of underlying diabetes HbA
glucose tolerance tests
Musculoskeletal disorders Review of medical notes and prescribed pharmacoth
discharge
Frailty test with hand-grip manometer, gait speed, s
test, and Short Physical Performance Battery includin
gait speed and getting in and out of a chair [101]
Renal impairment Electrolytes and renal function obtained during hosp
Calculation of body mass index
Respiratory disease Review of medical notes and prescribed pharmacoth
discharge
If high clinical suspicion of underlying respiratory di
lung function tests
Thyroid disease Review of medical notes and prescribed pharmacoth
discharge
If high clinical suspicion of, or historical lack of scree
thyroid function tests (including thyroid stimulating
levels) at hospital admission
Sleep disorders Review of medical notes and prescribed sleep suppo
If high clinical suspicion of sleep disordered breathin
formal sleep studies
Use of a screening questionnaire in hospital to ident
sleep-disordered breathing (135)managementwill be appliedwithin the community/out-patient setting.
A suitably qualiﬁed health professional (such as an experienced nurse
with relevant qualiﬁcations) has the capacity to generate realistic and
achievable care/action plans when — a) consulting and assessing pa-
tients in their home and then b) consulting with the wider health care
team to determine what can be done to meet the patient's needs
[24–26].
4.4. Step 4: Support individualised, home-based, multidisciplinary, case
management to supplement standard HF management
As recently articulated in the AHA/ACC/HHS Strategies to Enhance
Application of Clinical Practice Guidelines in Patients with Cardiovascu-
lar Disease and Comorbid Conditions [27], there is a compelling imper-
ative to adjust management strategies in the setting of multimorbidity,
and standard HF management is no exception. Beyond recognising and
characterising multimorbidity (see recommendations 1–3), strategic
plans that are robust (i.e., can be applied in different health care systems
with variable personnel, capacity and resources), ﬂexible, feasible, cost-
effective and focused on addressing each problem in the broader con-
text need to be formulated.
4.4.1. Management options
Disease management has demonstrated beneﬁt for improving clini-
cal outcomes. In the last two decades, a variety of robust HF disease
management approaches have been developed and tested, aimed at im-
provingHF outcomes and reducing hospitalisations [26,28–31]. Numer-
ous meta-analyses have documented the effectiveness of disease
management programmes for HF [32–40]. However, implementationDeﬁnition/deﬁcit threshold
Serum Hb level b 130 (women)/b120 g/L (men) [126,127]
harmacotherapy
- 12-lead ECG,
ing
Conﬁrmation of AF, other atrial arrhythmias, 2nd or 3rd degree
heart block, VT/VF with prescription of anti-arrhythmic therapy
or pacemaker/deﬁbrillator device [128]
) tool prior to Documented diagnosis of dementia or MoCA score b 26 out of a
maximal possible score of 30 [129]
tal discharge by
prescribed
re
Positive response to depressive symptoms and/or conﬁrmed
diagnosis (with active anti-depressant/anxiolytic) of depression
or anxiety
erapy at
1c and/or
Documented diagnosis of Type 2 Diabetes or obesity BMI N 30
kg/m2 plus dyslipidaemia and/or hypertension (metabolic
syndrome)
erapy at
ix-minute walk
g static balance,
Documented diagnosis of arthritis, osteoporosis, gout or any
other musculoskeletal condition requiring active therapy (e.g.
anti-inﬂammatory or analgesia)
ital admission Estimated glomerular ﬁltration rate b 60 mL/min/1.73 m2
[132]
erapy at
sease – formal
Lung function conﬁrmation of COPD, asthma and/or other chronic
pulmonary condition requiring active treatment [133]
erapy at
ning, perform
hormone
Documented hyper/
hypothyroidism based on according to national standards with
associated anti-thyroid or thyroxine replacement therapy [134]
rt device.
g perform
ify those with
Documented diagnosis of obstructive or central sleep disordered
breathing
5S. Stewart et al. / International Journal of Cardiology 212 (2016) 1–10of these programmes in clinical practice is highly variable. This is
reﬂected in a recent study conﬁrmingwide variation in the care provid-
ed to HF patients after discharge from the hospital [41]. A pooled analy-
sis of ten HF disease management RCTs highlighted that the essential
components of these programmes in reducing the number and length
of hospital admissions were multidisciplinary, team-based care that in-
cluded in-person communication between case managers, physicians
and patients [42].
It is notable that much of the evidence-base supporting HF disease
management programmes, for both historical and practical reasons,
has been primarily focused on relatively less complex cases, and thus
is less applicable to the populationwith HF andmultimorbidity. Yet, ep-
idemiological data show that patients hospitalised with HF are becom-
ing increasingly older (with associated multimorbidity rising at the
same time) [43–45]. Accordingly, more contemporary clinical trials of
HF management are dealing with older and more complex cases [46,
47]; particularlywhen compared to earlier trials focussing onmanaging
HF patients on an outpatient/ambulatory basis (the predominantmodel
of care inmany parts of theworld [48]. Unfortunately, therefore, the rel-
evance of previously effective management programmes in HF is likely
to be eroded by an increasing proportion of patients with HF and
multimorbidity with more challenging clinical priorities. Indeed, this
may explain the neutral results of trials of more HF-centric interven-
tions such as the COACH Study [49] and those applying remotemonitor-
ing techniques [50]. In comparison, positive results of home-based
management when compared to clinic-based treatment in the
WHICH? Trial [25] suggests a promising approach for those with HF
andmultimorbidity. To our knowledge, however, there are nodeﬁnitive
approaches to improve typically poor health outcomes that extend be-
yond standard HF management models of care.
The inherent complexity of managingmultiple comorbid conditions
is exacerbated by issues such as frailty, social isolation, impaired cogni-
tion and limited income that frequently negatively impact on sufferers
of HF, who are typically elderly [51–53]. Although practical and
disease-related issues are often closely interrelated [16,54–56], com-
plexity is often overlooked, adversely affecting quality of life, hospital
admission risk and survival [57–59]. Recent research reveals that it is
these very complex, multimorbid or high-risk patients who stand to
beneﬁt most from home-based patient-centred management
programmes [60]. From a health-cost perspective, the home-based ap-
proach to patient-centred management has been shown to be more
both clinically beneﬁcial (reduced hospital stay and prolonged survival)
and cost-effective when compared to an equivalent specialist HF clinic
in the head-to-head WHICH? Trial. Notably this trial speciﬁcally
targeted older patients with HF and multimorbidity [61]. Taken togeth-
er, these ﬁndings support the need for a paradigm shift — away from
diseasemanagement, which by deﬁnition targets a speciﬁc primary dis-
ease (e.g. HF), to a more holistic approach, which considers each condi-
tion in the broader context of competing morbidities and seeks to
design care in a way that optimises patient-centred outcomes
(i.e., patient-centred care).
4.4.2. Coordinating care in the setting of multimorbidity in HF
Interventions addressing multimorbidity and clinical complexity in
this population have the potential to reduce hospitalisations and pro-
long survival beyond that achieved by traditional disease management
and transitional care programmes. The latter targets poor communica-
tion and poorly coordinated transitions at hospital discharge that con-
tribute to negative health outcomes and increases the ﬁnancial burden
on the healthcare system (i.e., adverse events and increased
hospitalisations) [62]. Transitional care is effective in older adults with
HF who require complex care [63]. However, transitional care typically
continues for at most 3-months after hospital discharge, which risks re-
admission if self-care is not mastered and/or comorbid conditions are
not stabilised during that period. Although interventions for speciﬁc dis-
ease combinations have been tested (e.g., HF and diabetes) [64–67],clinical guidelines integrating the care of multiple conditions are rare.
[68]. Other approaches such as interdisciplinary primary care [69] and
interdisciplinary teams for nursing home residents [70] are in the
early phases of testing. Two promising interventions for multimorbidity
are patient-centred medical homes [71] and Guided Care [72–74]; both
of which have the potential to overcome the challenge of home-bound
individuals accessing community resources [75]. Likewise, the effective-
ness of physician house call programmes [76], as well home-support
with a more diverse team such as the CAPABLE team (comprising a
nurse, an occupational therapist and a handyman) are being evaluated
[77,78].
4.4.3. An emphasis on self-care
Self-care, important in any health condition, is particularly crucial for
patients with complex illnesses and comorbidity. The seminal work in
deﬁning self-care in adults with chronic illness has been undertaken
by Riegel and colleagues [79–81], who have conducted numerous stud-
ies aimed at understanding [82–86] and strengthening the ability of pa-
tients to perform self-care activities including adherence tomedications
and diet, as well as the detection and management of symptoms
[87–89]. Encouragingly, a recent pilot study demonstrated that in a pre-
dominantly minority HF sample with signiﬁcant multimorbidity, a tai-
lored home-based intervention using motivational interviewing and
skill-based education [87,89] achieved a statistically signiﬁcant and clin-
ically meaningful improvement in self-care that exceeded that of stan-
dard care [90,91]. Furthermore, hospitalisations unrelated to HF were
less frequent in the group receiving the intervention [92]. Overall,
there is good evidence to suggest that enhanced self-care can decrease
symptom severity, improve health related quality of life (HRQoL),
delay acute decompensation, and prevent hospitalisation in HF patients
[93–95].
4.4.4. A carer-centred approach
Given that self-caremay be particularly challenging for those HF pa-
tients with comorbid conditions such cognitive impairment [96], it is
vital that the role of the family and other caregivers be recognised and
supported. A recent systematic narrative review revealed that despite
the pivotal role played by caregivers in the care of HF patients, their
needs have not been clearly understood [97]. Three major areas of
need identiﬁed were, 1) psychosocial support to maintain a sense of
normalcy, 2) support with daily living, and 3) support navigating the
healthcare system. Although health professionals agree that patient
and caregiver uncertainty and unmet needs are major problems, they
feel lacking in knowledge, opportunities, or have adequate support to
improve the situation [98]. In order to improve outcomes for both care-
givers and HF patients, it seems clear that an individualised, person and
family-centred approach is required and must address issues arising
both from HF and from multimorbidity. In addition, it is vital for future
research to focus on how to optimally support and assist caregivers.
4.4.5. Applying case management in multimorbidity
Casemanagement is a collaborative process used to assess, plan, im-
plement, coordinate, monitor, and evaluate the services required to
meet a patient's health and human service needs [99]. The casemanage-
ment process is characterised by communication, resource manage-
ment, and advocacy with a focus on promoting quality and cost-
effective care. A key component of casemanagement, aswith other suc-
cessful diseasemanagement strategies, is a post-discharge home visit to
chronically ill, older adults who have complex social and environmental
issues (e.g., social isolation, ﬁnancial stress) that are rarely recognised
and addressed in routine clinical care [57–59]. In addition to shifting
the locus of control to the patient and assessing any residual signs of
clinical instability, a post-discharge home visit permits a physical
walk-through of the home with the patient, noting any environmental
issues that would compromise safety, most notably entry sites and
steps, bathroom areas and ﬂooring (e.g. loose rugs that may require
6 S. Stewart et al. / International Journal of Cardiology 212 (2016) 1–10attention for those with physical frailty). At the same time, this visit al-
lows the case manager to assess and support self-care abilities in a natu-
ralistic environment; permitting them to tailor interventions to address
the individual characteristics of the recipient [100], and focussing on
skill rather than simply knowledge [87,89]. Additionally, including
physiotherapy-based treatmentsmay be beneﬁcial as it has been recent-
ly shown that physiotherapy assists in falls prevention and reducing
functional deﬁcits in thosewith cardiovascular disease [101]. Speciﬁcally,
aerobic or resistance training can assist to improve physical performance
and HRQoL, and may increase the probability of older adults remaining
independent [101,102], with home-based exercise programmes found
to be as effective as supervised exercise programmes [103,104].
The fundamental role of the case manager (typically an experienced
nurse with relevant post-graduate qualiﬁcations and excellent commu-
nication skills), is coordination and navigation, marshalling both per-
sonnel and resources needed to carry out required patient care
activities [105]; this includes involving families and caregivers. The
casemanager is responsible for exchanging information among the var-
ious providers to help ensure that the patient's needs and preferences
for health services and information are met [106]. Given the complexity
and potential for competing priorities in this clinical setting, it is critical
that the need for all therapies, especially those with risk for harm, be
critically assessed. For example, polypharmacy is ubiquitous in this pa-
tient population and a process of “de-prescribing” should be considered.
This may include weaning central nervous system-active medicines
(benzodiazepines, opioids), corticosteroids, and even cardiovascular
drugs (e.g. statins, beta-blockers) over a timeframe of weeks to months
[107,108].4.5. Step 5: Evaluate health outcomeswell beyond acute hospitalisation and
encompass all-cause events and a person-centred perspective in affected
individuals
Despite an understandable focus on immediate and costly rebounds
to hospital in the short-term (i.e. within 30-days) [109–112], there is a
strong rationale for adopting a longer and more holistic perspective to
reﬂect the entire patient journey. The classical description of the natural
history of HF reinforces this point; periods of clinical instability are typ-
ically interspersed with periods of relative stability [113]. Clinical stud-
ies of disease management programmes often adopt singular endpoints
(e.g. risk of re-hospitalisation) over a short period of time and/or con-
ﬁne analyses to those events relating to the syndrome (i.e., HF speciﬁc).
However, such an approach is limited from both a patient and health
service perspective because there is clear potential for longer survival
free from all-cause hospitalisation andwith improved HRQoL. In simple
terms, restricting follow-up to a short-time period (e.g. 30-days to 3-
months) belies the complex interplay between short-term and long-
term stability with respect to the potential beneﬁt of more intensive
management. For example, a “therapeutic” early readmission may re-
sult in fewer hospital days and better quality of life over the ensuing
12-month period.
These considerations do not undermine the importance of monitor-
ing short-term outcomes; particularly when one considers that 20–25%
of HF patients are readmitted within 30-days of hospital discharge [13].
Due to the costs of hospitalisation [10], scrutiny of readmissions has in-
tensiﬁed in many countries. In this regard, multimorbidity has been
identiﬁed as playing a critical role in driving both early and late
readmissions inHF [18]. Indeed, two-thirds of patients readmittedwith-
in 30-days are hospitalised for a condition other than HF [13]. On this
basis, there is a strong rationale to examine the overall pattern of mor-
bidity and mortality (i.e. on an all-cause basis) over the longer-term;
particularly when considering the pattern of multimorbidity present
(derived from systematic proﬁling). Concurrently, the desire to involve
patients in setting their own goals provides a strong argument for eval-
uating the relative success of management from a person-centredperspective, such as patient-reported HRQoL and satisfaction with
health service delivery.
Fig. 2: Pragmatic interpretation of how the 5 key recommendations
for improving health outcomes in HF and multimorbidity might be ap-
plied on a differential basis, illustrates how the ﬁve steps outlined
abovemight be applied to improve health outcomes in this increasingly
common patient cohort; as suggested by this ﬁgure, patients with HF
and multimorbidity now represent the majority of those hospitalised
with HF. However, future research is required to determine how to
apply these steps in a cost-efﬁcient manner (including the use of infor-
mation technology to facilitate proﬁling and communication strategies)
and, to determine if the steps do indeed achieve better health outcomes
in a range of health care settings.
5. Discussion
There is overwhelming evidence that multimorbidity in HF is a
growing problemwithin an ageing population of HF patients. For exam-
ple, according to U.S. Census Bureau projections, between 2000 and
2030, those 65 years andover are expected to increase from34.8million
to over 70.3 million. In addition, those aged ≥85 years are the fastest
growing age group, and the number of 85+ year olds in the US is ex-
pected to increase ﬁvefold by 2050 [114]. Since approximately 75% of
older Americans have two or more chronic conditions, the number of
patients with HF and multimorbidity will inevitably continue to rise
[115]. Not only is multimorbidity becoming more common, it is associ-
ated with poor health outcomes that potentially defy disease manage-
ment strategies developed for younger and less complex cases of HF.
As such, without pro-activemanagement strategies to stabilise the clin-
ical status of affected individuals in the longer-term, progression to ge-
riatric syndromes such as falls, worsening renal function, and repetitive
hospitalisations that ultimately lead to disability, frailty, loss of indepen-
dence, and death will continue to occur with accelerating frequency
[114,115].
The potential for an increasing pool of patients with HF and
multimorbidity to generate an unsustainable wave of patients with
complex health care needs that are currently poorly served by existing
health systems cannot be over-stated. As previously suggested by our
group [15], reducing hospitalisations for any particular problem (e.g.
acute decompensated HF) has the potential for avoiding deleterious
consequences of hospitalisation itself, including delirium, iatrogenic ill-
ness, infections, deconditioning, sarcopenia, and increased falls risk.
Recognising and addressing these risks and potential adverse effects is
critical for reducing disability and optimising long-term health out-
comes. For example, sarcopenia represents an increasingly important
health problem in older adults [116]. For theHF patient, an initial hospi-
tal admissionwith associated bed-rest is likely to exacerbate underlying
muscle dysfunction and wasting [117]; increasing the risk of recurrent
hospitalisation in the absence of proactivemobilisation and occupation-
al therapy [118,119]. Similarly, catastrophic fall risk increases exponen-
tially in the hospital setting; something that is routinely observed in the
clinical management of older patients with HF and multimorbidity.
Therefore, more pro-active efforts to minimise age-related physical de-
cline and dysfunction are necessary [120].
In writing this position paper, we explicitly acknowledge the inher-
ent limitations of our review of the literature relating to HF and
multimorbidity in respect to a predominant focus on co-morbidity as
opposed to multimorbid interactions (the latter reﬂecting the limita-
tions of the literature in this regard). The prevalence and inﬂuence of
speciﬁc conditions (including the ten conditions of speciﬁc interest)
will undoubtedly vary within different HF populations. We have made
no distinction between HF with reduced or preserved ejection fraction.
At the same time, we have not focused on the most common anteced-
ents of HF (hypertension and ischaemic heart disease) as we believe
these are routinely addressed in the majority of patients with HF. This
paper is not a guideline or a systematic review. However, we have
Fig. 2. Pragmatic interpretation of 5 key recommendations.
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er than speciﬁc recommendations for clinical management; as
emphasised repeatedly, management needs to be individualised while
considering the type of information provided in Supplementary Table 1.
As emphasised throughout this position paper, any approach to the
complex issues engendered by an increasing number of individuals
with HF and multimorbidity requires an overarching, strategic ap-
proach. Our clinical framework for action, comprising the ﬁve key
steps of ARISE-HF, can be best viewed through the prism of a previously
published policy framework (and overarching goals) for improving
health outcomes and HRQoL in individuals with multimorbidity
[121–123]:
• Foster health care and public health system changes to improve the
health of with HF and multimorbidity. This includes developing
evidence-supported models to improve care coordination, deﬁning
appropriate health care outcomes and providing incentives to make
positive changes to the health care system.
• Facilitate self-care, wherever possible, with an equal emphasis on fa-
cilitating home and community-based services.
• Provide better tools, strategies and information to health professionals
directly managing individuals with multimorbidity so they can im-
prove the effectiveness of care delivery and subsequent health out-
comes.
• Undertake health services research to ﬁll critical gaps in our under-
standing of multimorbidity in HF with an emphasis on clinical, com-
munity, and patient-centred studies that seek to develop cost-
effective models of care.
In the future, we anticipate a greater focus on managing
multimorbidity in HF in clinical practice guidelines butwith a far greater
emphasis on principles of individualised management rather than spe-
ciﬁc instructions.We emphasise, therefore, that this clinical framework,generated from a diverse collection of health professionals with practi-
cal expertise in themanagement of patients with multimorbidity, com-
plements existing HF guidelines [124,125]. Our future challenge is to
determine how best to incorporate what we have proposed into clinical
practice and to demonstrate that it does indeed, as we expect, improve
health outcomes in this growing patient population
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2016.03.001.
Conﬂict of interest
The authors report no relationships that could be construed as a con-
ﬂict of interest.
Acknowledgements
SS and MJC are supported by the National Health and Medical Re-
search Council of Australia (1041796 and 1032934). WSW is supported
by an Institutional Development Award (IDeA) from the National Insti-
tute of General Medical Sciences of the National Institutes of Health
under grant number U54-GM104941. The authors have stated that
they have no relationships relevant to the contents of this paper to
disclose.
References
[1] Robert Wood Johnson Foundation, Chronic Care: Making the Case for Ongoing
Care, Robert Wood Johnson Foundation, 2010.
[2] B.W. Ward, J.S. Schiller, Prevalence of multiple chronic conditions among US
adults: estimates from the National Health Interview Survey, 2010, Prev. Chronic
Dis. 10 (2013) E65.
[3] Centers for Medicare & Medicaid Services, Chronic conditions Among Medicare
Beneﬁciaries, Chart Book(Baltimore, MD) 2011.
[4] K.A. Lochner, C.S. Cox, Prevalence of multiple chronic conditions among Medicare
beneﬁciaries, United States, 2010, Prev. Chronic Dis. 10 (2013) E61.
.
8 S. Stewart et al. / International Journal of Cardiology 212 (2016) 1–10[5] H.C. Britt, C.M. Harrison, G.C. Miller, S.A. Knox, Prevalence and patterns of
multimorbidity in Australia, Med. J. Aust. 189 (2) (2008) 72–77.
[6] A.A. Uijen, E.H. van de Lisdonk, Multimorbidity in primary care: prevalence and
trend over the last 20 years, Eur. J. Gen. Pract. 14 (Suppl. 1) (2008) 28–32.
[7] J.M. Longman, M. Rolfe, M.D. Passey, K.E. Heathcote, D.P. Ewald, T. Dunn, et al., Fre-
quent hospital admission of older people with chronic disease: a cross-sectional
survey with telephone follow-up and data linkage, BMC Health Serv. Res. 12
(2012) 373.
[8] M.E. Salive, Multimorbidity in older adults, Epidemiol. Rev. 35 (2013) 75–83.
[9] J.B. Braunstein, G.F. Anderson, G. Gerstenblith, W. Weller, M. Niefeld, R. Herbert,
et al., Noncardiac comorbidity increases preventable hospitalizations andmortality
amongMedicare beneﬁciaries with chronic heart failure, J. Am. Coll. Cardiol. 42 (7)
(2003) 1226–1233.
[10] P.A. Heidenreich, N.M. Albert, L.A. Allen, D.A. Bluemke, J. Butler, G.C. Fonarow, et al.,
Forecasting the impact of heart failure in the United States: a policy statement
from the American Heart Association, Circ. Heart Fail. 6 (3) (2013) 606–619.
[11] S.F. Jencks, M.V. Williams, E.A. Coleman, Rehospitalizations among patients in the
Medicare fee-for-service program, N. Engl. J. Med. 360 (14) (2009) 1418–1428.
[12] E.H. Bradley, L.A. Curry, H.M. Krumholz, Strategies to reduce heart failure
readmissions, JAMA 311 (11) (2014) 1160.
[13] K. Dharmarajan, A.F. Hsieh, Z. Lin, H. Bueno, J.S. Ross, L.I. Horwitz, et al., Diagnoses
and timing of 30-day readmissions after hospitalization for heart failure, acute
myocardial infarction, or pneumonia, JAMA 309 (4) (2013) 355–363.
[14] V.H. Chong, J. Singh, H. Parry, J. Saunders, F. Chowdhury, D.M. Mancini, et al., Man-
agement of non-cardiac comorbidities in chronic heart failure, Cardiovasc. Ther. 33
(5) (2015) 300–315.
[15] S. Stewart, B. Riegel, D.R. Thompson, Addressing the conundrum of multimorbidity
in heart failure: do we need a more strategic approach to improve health out-
comes? Eur. J. Cardiovasc. Nurs. 15 (1) (2016) 4–7.
[16] F.K. Triposkiadis, J. Skoularigis, Prevalence and importance of comorbidities in pa-
tients with heart failure, Curr. Heart Fail. Rep. 9 (4) (2012) 354–362.
[17] M.E. Tinetti, T.R. Fried, C.M. Boyd, Designing health care for the most common
chronic condition — multimorbidity, JAMA 307 (23) (2012) 2493–2494.
[18] R.E. Foraker, K.M. Rose, C.M. Suchindran, P.P. Chang, A.M. McNeill, W.D. Rosamond,
Socioeconomic status, Medicaid coverage, clinical comorbidity, and rehospitaliza-
tion or death after an incident heart failure hospitalization: atherosclerosis risk in
communities cohort (1987 to 2004), Circ. Heart Fail. 4 (3) (2011) 308–316.
[19] C.S. Lee, C.V. Chien, J.T. Bidwell, J.M. Gelow, Q.E. Denfeld, R. Masterson Creber, et al.,
Comorbidity proﬁles and inpatient outcomes during hospitalization for heart fail-
ure: an analysis of the U.S. Nationwide inpatient sample, BMC Cardiovasc. Disord.
14 (2014) 73.
[20] J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Bohm, K. Dickstein,
et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart
failure 2012: the task force for the diagnosis and treatment of acute and chronic
heart failure 2012 of the European Society of Cardiology. Developed in collabora-
tion with the Heart Failure Association (HFA) of the ESC, Eur. Heart J. 33 (14)
(2012) 1787–1847.
[21] C.W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., M.H. Drazner, et al., 2013
ACCF/AHA guideline for the management of heart failure: executive summary: a
report of the American College of Cardiology Foundation/American Heart Associa-
tion Task Force on practice guidelines, Circulation 128 (16) (2013) 1810–1852.
[22] J.A. Whitty, S. Stewart, M.J. Carrington, A. Calderone, T. Marwick, J.D. Horowitz,
et al., Patient preferences and willingness-to-pay for a home or clinic based pro-
gram of chronic heart failure management: ﬁndings from the Which? trial, PLoS
One 8 (3) (2013) e58347.
[23] National Heart Foundation of Australia, Multidisciplinary Care for People with
Chronic Heart Failure. Principles and Recommendations for Best Practice, 2010.
[24] S. Stewart, J. Ball, J.D. Horowitz, T.H. Marwick, G. Mahadevan, C. Wong, et al., Stan-
dard versus atrial ﬁbrillation-speciﬁc management strategy (SAFETY) to reduce re-
current admission and prolong survival: pragmatic, multicentre, randomised
controlled trial, Lancet 385 (9970) (2015) 774–784.
[25] S. Stewart, M.J. Carrington, T.H. Marwick, P.M. Davidson, P. Macdonald, J.D.
Horowitz, et al., Impact of home versus clinic-based management of chronic
heart failure: the WHICH? (Which Heart Failure Intervention Is Most Cost-
Effective & Consumer Friendly in Reducing Hospital Care) multicenter, random-
ized trial, J. Am. Coll. Cardiol. 60 (14) (2012) 1239–1248.
[26] S. Stewart, J.E. Marley, J.D. Horowitz, Effects of a multidisciplinary, home-based inter-
vention on unplanned readmissions and survival among patients with chronic con-
gestive heart failure: a randomised controlled study, Lancet 354 (9184) (1999)
1077–1083.
[27] D.K. Arnett, R.A. Goodman, J.L. Halperin, J.L. Anderson, A.K. Parekh, W.A. Zoghbi,
AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in
patients with cardiovascular disease and comorbid conditions: from the
American Heart Association, American College of Cardiology, and US Department
of Health and Human Services, Circulation 130 (18) (2014) 1662–1667.
[28] L. Blue, E. Lang, J.J. McMurray, A.P. Davie, T.A. McDonagh, D.R. Murdoch, et al.,
Randomised controlled trial of specialist nurse intervention in heart failure, BMJ
323 (7315) (2001) 715–718.
[29] B. Riegel, B. Carlson, D. Glaser, P. Hoagland,Which patients with heart failure respond
best to multidisciplinary disease management? J. Card. Fail. 6 (4) (2000) 290–299.
[30] B. Riegel, B. Carlson, D. Glaser, T. Romero, Randomized controlled trial of telephone
case management in Hispanics of Mexican origin with heart failure, J. Card. Fail. 12
(3) (2006) 211–219.
[31] B. Riegel, B. Carlson, Z. Kopp, B. LePetri, D. Glaser, A. Unger, Effect of a standardized
nurse case-management telephone intervention on resource use in patients with
chronic heart failure(see comment) Arch. Intern. Med. 162 (6) (2002) 705–712.[32] S. Ara, A literature review of cardiovascular disease management programs in
managed care populations, J. Manag. Care Pharm. 10 (4) (2004) 326–344.
[33] A. Gohler, J.L. Januzzi, S.S. Worrell, K.J. Osterziel, G.S. Gazelle, R. Dietz, et al., A sys-
tematic meta-analysis of the efﬁcacy and heterogeneity of disease management
programs in congestive heart failure, J. Card. Fail. 12 (7) (2006) 554–567.
[34] J. Gonseth, P. Guallar-Castillon, J.R. Banegas, F. Rodriguez-Artalejo, The effective-
ness of disease management programmes in reducing hospital re-admission in
older patients with heart failure: a systematic review and meta-analysis of pub-
lished reports, Eur. Heart J. 25 (18) (2004) 1570–1595.
[35] A.L. Leppin, M.R. Gionfriddo, M. Kessler, J.P. Brito, F.S. Mair, K. Gallacher, et al.,
Preventing 30-day hospital readmissions: a systematic review and meta-analysis
of randomized trials, JAMA Intern. Med. 174 (7) (2014) 1095–1107.
[36] F.A. McAlister, F.M. Lawson, K.K. Teo, P.W. Armstrong, A systematic review of ran-
domized trials of disease management programs in heart failure, Am. J. Med. 110
(5) (2001) 378–384.
[37] J.J. Ofman, E. Badamgarav, J.M. Henning, K. Knight, A.D. Gano Jr., R.K. Levan,
et al., Does disease management improve clinical and economic outcomes in
patients with chronic diseases? A systematic review, Am. J. Med. 117 (3)
(2004) 182–192.
[38] R. Roccaforte, C. Demers, F. Baldassarre, K.K. Teo, S. Yusuf, Effectiveness of compre-
hensive disease management programmes in improving clinical outcomes in heart
failure patients. A meta-analysis, Eur. J. Heart Fail. 7 (7) (2005) 1133–1144.
[39] L.A. Savard, D.R. Thompson, A.M. Clark, A meta-review of evidence on heart failure
disease management programs: the challenges of describing and synthesizing ev-
idence on complex interventions, Trials 12 (2011) 194.
[40] D.J. Whellan, V. Hasselblad, E. Peterson, C.M. O'Connor, K.A. Schulman,
Metaanalysis and review of heart failure disease management randomized con-
trolled clinical trials, Am. Heart J. 149 (4) (2005) 722–729.
[41] R.D. Kociol, L. Liang, A.F. Hernandez, L.H. Curtis, P.A. Heidenreich, C.W. Yancy, et al.,
Are we targeting the right metric for heart failure? Comparison of hospital 30-day
readmission rates and total episode of care inpatient days, Am. Heart J. 165 (6)
(2013) 987–994 (e1).
[42] J. Sochalski, T. Jaarsma, H.M. Krumholz, A. Laramee, J.J. McMurray, M.D. Naylor,
et al., What works in chronic care management: the case of heart failure, Health
Aff. 28 (1) (2009) 179–189.
[43] A.J. Pefoyo, S.E. Bronskill, A. Gruneir, A. Calzavara, K. Thavorn, Y. Petrosyan, et al., The
increasing burden and complexity of multimorbidity, BMC Public Health 15 (2015)
415.
[44] M. Schaufelberger, K. Swedberg, M. Koster, M. Rosen, A. Rosengren, Decreasing
one-year mortality and hospitalization rates for heart failure in Sweden; data
from the Swedish Hospital Discharge Registry 1988 to 2000, Eur. Heart J. 25 (4)
(2004) 300–307.
[45] S. Stewart, K. MacIntyre, S. Capewell, J.J. McMurray, Heart failure and the aging
population: an increasing burden in the 21st century? Heart 89 (1) (2003)
49–53.
[46] A. Driscoll, L. Worrall-Carter, D.L. Hare, P.M. Davidson, B. Riegel, A. Tonkin, et al.,
Evidence-based chronic heart failure management programs: reality or myth?
Qual. Saf. Health Care 18 (6) (2009) 450–455.
[47] F.A. McAlister, S. Stewart, S. Ferrua, J.J. McMurray, Multidisciplinary strategies for
the management of heart failure patients at high risk for admission: a systematic
review of randomized trials, J. Am. Coll. Cardiol. 44 (4) (2004) 810–819.
[48] H. Krum, A. Driscoll, Management of heart failure, Med. J. Aust. 199 (5) (2013)
334–339.
[49] T. Jaarsma, M.H. van der Wal, I. Lesman-Leegte, M.L. Luttik, J. Hogenhuis, N.J.
Veeger, et al., Effect of moderate or intensive disease management program on
outcome in patients with heart failure: Coordinating Study Evaluating Outcomes
of Advising and Counseling in Heart failure (COACH), Arch. Intern. Med. 168 (3)
(2008) 316–324.
[50] S.I. Chaudhry, J.A.Mattera, J.P. Curtis, J.A. Spertus, J. Herrin, Z. Lin, et al., Telemonitoring
in patients with heart failure, N. Engl. J. Med. 363 (24) (2010) 2301–2309.
[51] K.E. Freedland, R.M. Carney, Psychosocial considerations in elderly patients with
heart failure, Clin. Geriatr. Med. 16 (3) (2000) 649–661.
[52] R. Kerzner, M.W. Rich, Management of heart failure in the elderly, Curr. Cardiol.
Rep. 5 (3) (2003) 223–228.
[53] E.B. Norberg, K. Boman, B. Lofgren, M. Brannstrom, Occupational performance and
strategies for managing daily life among the elderly with heart failure, Scand. J.
Occup. Ther. 21 (5) (2014) 392–399.
[54] S. Ather, W. Chan, B. Bozkurt, D. Aguilar, K. Ramasubbu, A.A. Zachariah, et al., Im-
pact of noncardiac comorbidities on morbidity and mortality in a predominantly
male population with heart failure and preserved versus reduced ejection fraction,
J. Am. Coll. Cardiol. 59 (11) (2012) 998–1005.
[55] C.C. Lang, D.M. Mancini, Non-cardiac comorbidities in chronic heart failure, Heart
93 (6) (2007) 665–671.
[56] J.M. Valderas, B. Starﬁeld, B. Sibbald, C. Salisbury, M. Roland, Deﬁning comorbidity:
implications for understanding health and health services, Ann. Fam. Med. 7 (4)
(2009) 357–363.
[57] A.R. Moraska, A.M. Chamberlain, N.D. Shah, K.S. Vickers, T.A. Rummans, S.M.
Dunlay, et al., Depression, healthcare utilization, and death in heart failure: a com-
munity study, Circ. Heart Fail. 6 (3) (2013) 387–394.
[58] K. Radhakrishnan, K. Bowles, A. Hanlon, M. Topaz, J. Chittams, A retrospective
study on patient characteristics and telehealth alerts indicative of key medical
events for heart failure patients at a home health agency, Telemed. J. E Health 19
(9) (2013) 664–670.
[59] J.H. Retrum, J. Boggs, A. Hersh, L. Wright, D.S. Main, D.J. Magid, et al., Patient-
identiﬁed factors related to heart failure readmissions, Circ. Cardiovasc. Qual. Out-
comes 6 (2) (2013) 171–177.
9S. Stewart et al. / International Journal of Cardiology 212 (2016) 1–10[60] S. Stewart, J. Wiley, Y.K. Chan, J. Ball, D.R. Thompson, M.J. Carrington, Prolonged
event-free survival in more complex cases of heart disease: outcome data from
1,226 patients from 3 randomised trials of nurse-led, multidisciplinary home-
based intervention, Late-Breaking Clinical Trial Presentation, European Society of
Cardiology Scientiﬁc Congress, London, UK, 2015.
[61] S. Stewart, M.J. Carrington, J.D. Horowitz, T.H. Marwick, P.J. Newton, P.M. Davidson,
et al., Prolonged impact of home versus clinic-based management of chronic heart
failure: extended follow-up of a pragmatic, multicentre randomized trial cohort,
Int. J. Cardiol. 174 (3) (2014) 600–610.
[62] L. Sweeney, A. Halpert, J. Waranoff, Patient-centered management of complex pa-
tients can reduce costs without shortening life, Am. J. Manag. Care 13 (2) (2007)
84–92.
[63] M.D. Naylor, D.A. Brooten, R.L. Campbell, G. Maislin, K.M. McCauley, J.S. Schwartz,
Transitional care of older adults hospitalizedwith heart failure: a randomized, con-
trolled trial, J. Am. Geriatr. Soc. 52 (5) (2004) 675–684.
[64] S.B. Dunbar, C.M. Reilly, R. Gary, M.K. Higgins, S. Culler, B. Butts, et al., Randomized
clinical trial of an integrated self-care intervention for persons with heart failure
and diabetes: quality of life and physical functioning outcomes, J. Card. Fail. 21
(9) (2015) 719–729.
[65] B.B. Granger, I. Ekman, A.F. Hernandez, T. Sawyer, M.T. Bowers, T.A. DeWald, et al.,
Results of the chronic heart failure intervention to improve MEdication adherence
study: a randomized intervention in high-risk patients, Am. Heart J. 169 (4) (2015)
539–548.
[66] S.D. Reed, M.P. Neilson, M. Gardner, Y. Li, A.H. Briggs, D.E. Polsky, et al., Tools for
economic analysis of patient management interventions in heart failure cost-effec-
tiveness model: a web-based program designed to evaluate the cost-effectiveness
of disease management programs in heart failure, Am. Heart J. 170 (5) (2015)
951–960.
[67] C.M. Reilly, J. Butler, S.D. Culler, R.A. Gary, M. Higgins, P. Schindler, et al., An eco-
nomic evaluation of a self-care intervention in persons with heart failure and dia-
betes, J. Card. Fail. 21 (9) (2015) 730–737.
[68] M.V. Pauly, Accountable care organizations and kidney disease care: health
reform innovation or more same-old, same-old? Am. J. Kidney Dis. 60 (4) (2012)
524–529.
[69] S.F. Metzelthin, E. van Rossum, L.P. de Witte, A.W. Ambergen, S.O. Hobma, W.
Sipers, et al., Effectiveness of interdisciplinary primary care approach to reduce dis-
ability in community dwelling frail older people: cluster randomised controlled
trial, BMJ 347 (2013) f5264.
[70] T. Rosenberg, Acute hospital use, nursing home placement, and mortality in a frail
community-dwelling cohort managed with primary integrated interdisciplinary
elder care at home, J. Am. Geriatr. Soc. 60 (7) (2012) 1340–1346.
[71] T.F. Page, S.A. Amofah, S. McCann, J. Rivo, A. Varghese, T. James, et al., CareManage-
ment Medical Home Center model: preliminary results of a patient-centered ap-
proach to improving care quality for diabetic patients, Health Promot. Pract. 16
(4) (2015) 609–616.
[72] C. Boult, L. Reider, B. Leff, K.D. Frick, C.M. Boyd, J.L. Wolff, et al., The effect of guided
care teams on the use of health services: results from a cluster-randomized con-
trolled trial, Arch. Intern. Med. 171 (5) (2011) 460–466.
[73] C.M. Boyd, C. Boult, E. Shadmi, B. Leff, R. Brager, L. Dunbar, et al., Guided care for
multimorbid older adults, Gerontologist 47 (5) (2007) 697–704.
[74] B. Leff, L. Reider, K.D. Frick, D.O. Scharfstein, C.M. Boyd, K. Frey, et al., Guided care
and the cost of complex healthcare: a preliminary report, Am. J. Manag. Care 15
(8) (2009) 555–559.
[75] J.M. Hollingsworth, S. Saint, R.A. Hayward, M.A. Rogers, L. Zhang, D.C. Miller, Spe-
cialty care and the patient-centered medical home, Med. Care 49 (1) (2011) 4–9.
[76] Centers for Medicare and Medicaid Services, Independance at Home Demonstra-
tion, Services Centers for Medicare and Medicaid Services, 2014 (USA).
[77] S.L. Szanton, J. Roth, M. Nkimbeng, J. Savage, R. Klimmek, Improving unsafe envi-
ronments to support aging independence with limited resources, Nurs. Clin. N.
Am. 49 (2) (2014) 133–145.
[78] S.L. Szanton, J.W. Wolff, B. Leff, R.J. Thorpe, E.K. Tanner, C. Boyd, et al., CAPABLE
trial: a randomized controlled trial of nurse, occupational therapist and handyman
to reduce disability among older adults: rationale and design, Contemp. Clin. Trials
38 (1) (2014) 102–112.
[79] B. Riegel, V.V. Dickson, A situation-speciﬁc theory of heart failure self-care, J.
Cardiovasc. Nurs. 23 (3) (2008) 190–196.
[80] B. Riegel, V.V. Dickson, K.M. Faulkner, The situation-speciﬁc theory of heart failure
self-care: revised and updated, J. Cardiovasc. Nurs. (2015) ([Epub ahead of print]).
[81] B. Riegel, T. Jaarsma, A. Stromberg, A middle-range theory of self-care of chronic ill-
ness, ANS Adv. Nurs. Sci. 35 (3) (2012) 194–204.
[82] V.V. Dickson, H. Buck, B. Riegel, Multiple comorbid conditions challenge heart
failure self-care by decreasing self-efﬁcacy, Nurs. Res. 62 (1) (2013) 2–9.
[83] V.V. Dickson, J.A. Deatrick, B. Riegel, A typology of heart failure self-care manage-
ment in non-elders, Eur. J. Cardiovasc. Nurs. 7 (3) (2008) 171–181.
[84] V.V. Dickson, N. Tkacs, B. Riegel, Cognitive inﬂuences on self-care decision making
in persons with heart failure, Am. Heart J. 154 (3) (2007) 424–431.
[85] B. Riegel, B. Carlson, Facilitators and barriers to heart failure self-care, Patient Educ.
Couns. 46 (2002) 287–295.
[86] B. Riegel, C.S. Lee, N. Albert, T. Lennie, M. Chung, E.K. Song, et al., From novice to
expert: conﬁdence and activity status determine heart failure self-care perfor-
mance, Nurs. Res. 60 (2) (2011) 132–138.
[87] V.V. Dickson, G.D. Melkus, S. Katz, A. Levine-Wong, J. Dillworth, C.M. Cleland, et al.,
Building skill in heart failure self-care among community dwelling older adults: re-
sults of a pilot study, Patient Educ. Couns. 96 (2) (2014) 188–196.
[88] V.V. Dickson, J. Nocella, H.W. Yoon, M. Hammer, G.D. Melkus, D. Chyun, Cardiovas-
cular disease self-care interventions, Nurs. Res. Pract. 2013 (2013) 407608.[89] V.V. Dickson, B. Riegel, Are we teaching what patients need to know? Building
skills in heart failure self-care, Heart Lung 38 (3) (2009) 253–261.
[90] R. Masterson Creber, M. Patey, V.V. Dickson, M. DeCesaris, B. Riegel, Motivational
Interviewing Tailored Interventions for Heart Failure (MITI-HF): study design
and methods, Contemp. Clin. Trials 41 (2015) 62–68.
[91] R. Masterson Creber, M. Patey, C.S. Lee, A. Kuan, B. Riegel, Motivational
Interviewing Tailored Interventions for Heart Failure (MITI-HF): randomized con-
trolled trial, Patient Educ. Couns. (2015) ([Epub ahead of print]).
[92] R. Masterson Creber, M. Patey, C.S. Lee, A. Kuan, C. Jurgens, B. Riegel, Motivational
interviewing to improve self-care for patients with chronic heart failure: MITI-HF
randomized controlled trial, Patient Educ. Couns. (2015) ([Epub ahead of print]).
[93] C.S. Lee, B. Carlson, B. Riegel, Heart failure self-care improves economic outcomes,
but only when self-care conﬁdence is high, J. Card. Fail. 13 (6) (2007) S75.
[94] C.S. Lee, D.K. Moser, T.A. Lennie, B. Riegel, Event-free survival in adults with heart
failure who engage in self-care management, Heart Lung 40 (1) (2011) 12–20.
[95] C.S. Lee, D.K. Moser, T.A. Lennie, N.C. Tkacs, K.B. Margulies, B. Riegel, Biomarkers of
myocardial stress and systemic inﬂammation in patients who engage in heart fail-
ure self-care management, J. Cardiovasc. Nurs. 26 (4) (2011) 321–328.
[96] V.V. Dickson, H. Buck, B. Riegel, A qualitativemeta-analysis of heart failure self-care
practices among individuals with multiple comorbid conditions, J. Card. Fail. 17 (5)
(2011) 413–419.
[97] L.C. Doherty, D. Fitzsimons, S.J. McIlfatrick, Carers' needs in advanced heart failure:
a systematic narrative review, Eur. J. Cardiovasc. Nurs. (2015) ([Epub ahead of
print]).
[98] S. Browne, S. Macdonald, C.R. May, U. Macleod, F.S. Mair, Patient, carer and profes-
sional perspectives on barriers and facilitators to quality care in advanced heart
failure, PLoS One 9 (3) (2014) e93288.
[99] Commission for Case Manager Certiﬁcation, 2014 [September 27, 2014]. Available
from: http://ccmcertiﬁcation.org/.
[100] C. Beck, J.C. McSweeney, K.C. Richards, P.K. Roberson, P.F. Tsai, E. Souder, Chal-
lenges in tailored intervention research, Nurs. Outlook 58 (2) (2010) 104–110.
[101] R. Gary, Evaluation of frailty in older adults with cardiovascular disease: incorpo-
rating physical performance measures, J. Cardiovasc. Nurs. 27 (2) (2012) 120–131.
[102] A. Knocke, Program description: physical therapy in a heart failure clinic,
Cardiopulm. Phys. Ther. J. 23 (3) (2012) 46–48.
[103] R.S. Taylor, H. Dalal, K. Jolly, T. Moxham, A. Zawada, Home-based versus centre-
based cardiac rehabilitation, Cochrane Database Syst. Rev. 1 (2010) CD007130.
[104] H.M. Dalal, A. Zawada, K. Jolly, T. Moxham, R.S. Taylor, Home based versus centre
based cardiac rehabilitation: Cochrane systematic review and meta-analysis, BMJ
340 (2010) b5631.
[105] K. McDonald, V. Sundaram, D. Bravada, R. Lewis, N. Lin, S. Kraft, et al., Care coordi-
nation. In closing the quality gap: a critical analysis of quality improvement strat-
egies technical review 9, 290-02-0017) Prepared by: Stanford-UCSF Evidence-
Based Practice Center, Agency for Healthcare Research and Quality, Rockville,
MD, 2007.
[106] National Quality Forum (NQF), Preferred Practices and Performance Measures for
Measuring and Reporting Care Coordination: A Consensus Report(Washington,
DC) 2010.
[107] C. Frank, E. Weir, Deprescribing for older patients, CMAJ 186 (18) (2014)
1369–1376.
[108] E. Reeve, To J, I. Hendrix, S. Shakib, M.S. Roberts, M.D.Wiese, Patient barriers to and
enablers of deprescribing: a systematic review, Drugs Aging 30 (10) (2013)
793–807.
[109] L.A. Allen, K.E. Smoyer Tomic, D.M. Smith, K.L. Wilson, I. Agodoa, Rates and predic-
tors of 30-day readmission among commercially insured and Medicaid-enrolled
patients hospitalized with systolic heart failure, Circ. Heart Fail. 5 (6) (2012)
672–679.
[110] E.H. Bradley, L. Curry, L.I. Horwitz, H. Sipsma, Y. Wang, M.N. Walsh, et al., Hospital
strategies associated with 30-day readmission rates for patients with heart failure,
Circ. Cardiovasc. Qual. Outcomes 6 (4) (2013) 444–450.
[111] M.B. Hernandez, R.S. Schwartz, C.R. Asher, E.V. Navas, V. Totfalusi, I. Buitrago, et al.,
Predictors of 30-day readmission in patients hospitalized with decompensated
heart failure, Clin. Cardiol. 36 (9) (2013) 542–547.
[112] R.Wexler, Early physician follow-up and 30-day readmission among older patients
with heart failure, JAMA 304 (7) (2010) 743 (author reply−4).
[113] S.J. Goodlin, Palliative care in congestive heart failure, J. Am. Coll. Cardiol. 54 (5)
(2009) 386–396.
[114] P.M. Ironside, M.E. Tagliareni, B. McLaughlin, E. King, A. Mengel, Fostering geriatrics
in associate degree nursing education: an assessment of current curricula and clin-
ical experiences, J. Nurs. Educ. 49 (5) (2010) 246–252.
[115] Agency for Healthcare Research and Quality, Developing Tools and Data for Re-
search and Policymaking, 2012.
[116] B.T. Wall, M.L. Dirks, L.J. van Loon, Skeletal muscle atrophy during short-term dis-
use: implications for age-related sarcopenia, Ageing Res. Rev. 12 (4) (2013)
898–906.
[117] D. Cuthbertson, K. Smith, J. Babraj, G. Leese, T. Waddell, P. Atherton, et al., Anabolic
signaling deﬁcits underlie amino acid resistance of wasting, aging muscle, FASEB J.
19 (3) (2005) 422–424.
[118] D.M. Needham, Mobilizing patients in the intensive care unit: improving neuro-
muscular weakness and physical function, JAMA 300 (14) (2008) 1685–1690.
[119] N. Stall, Tackling immobility in hospitalized seniors, CMAJ 184 (15) (2012)
1666–1667.
[120] T. Brown-O'Hara, Geriatric syndromes and their implications for nursing, Nursing
1-3 (2013).
[121] A.K. Parekh, R.A. Goodman, C. Gordon, H.K. Koh, The HHS, Interagency workgroup
on multiple chronic conditions. managing multiple chronic conditions: a strategic
10 S. Stewart et al. / International Journal of Cardiology 212 (2016) 1–10framework for improving health outcomes and quality of life, Public Health Rep.
126 (4) (2011) 460–471.
[122] A.K. Parekh, R. Kronick, M. Tavenner, Optimizing health for persons with multiple
chronic conditions, JAMA 312 (12) (2014) 1199–1200.
[123] US Department of Health and Human Services, Multiple Chronic Conditions — A
Strategic Framework: Optimum Health and Quality of Life for Individuals with
Multiple Chronic Conditions(Washington, DC) 2010.
[124] J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Bohm, K. Dickstein,
et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart
failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic
Heart failure 2012 of the European Society Of Cardiology. Developed in collabora-
tion with the Heart Failure Association (HFA) of the ESC, Eur. J. Heart Fail. 14 (8)
(2012) 803–869.
[125] C.W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., M.H. Drazner, et al., 2013
ACCF/AHA guideline for the management Of heart failure: executive summary: a
report of the American College of Cardiology Foundation/American Heart Associa-
tion Task Force on practice guidelines, J. Am. Coll. Cardiol. 62 (16) (2013)
e147–e239.
[126] S.R. Pasricha, S.C. Flecknoe-Brown, K.J. Allen, P.R. Gibson, L.P. McMahon, J.K. Olynyk,
et al., Diagnosis and management of iron deﬁciency anaemia: a clinical update,
Med. J. Aust. 193 (9) (2010) 525–532.
[127] G. Gregoratos, M.D. Cheitlin, A. Conill, A.E. Epstein, C. Fellows, T.B. Ferguson Jr.,
et al., ACC/AHA guidelines for implantation of cardiac pacemakers and
antiarrhythmia devices: a report of the American College of Cardiology/AmericanHeart Association Task Force on practice guidelines (committee on pacemaker im-
plantation), J. Am. Coll. Cardiol. 31 (5) (1998) 1175–1209.
[128] D.M.C. Doerﬂinger, Mental Status Assessment in Older Adults: Montreal Cognitive
Assessment: MoCA Version 7.1 (Original Version), 2012 (Virginia).
[129] B. Lowe, I. Wahl, M. Rose, C. Spitzer, H. Glaesmer, K. Wingenfeld, et al., A 4-item
measure of depression and anxiety: validation and standardization of the Patient
Health Questionnaire-4 (PHQ-4) in the general population, J. Affect. Disord. 122
(1–2) (2010) 86–95.
[130] T. Rutledge, V.A. Reis, S.E. Linke, B.H. Greenberg, P.J. Mills, Depression in heart fail-
ure a meta-analytic review of prevalence, intervention effects, and associations
with clinical outcomes, J. Am. Coll. Cardiol. 48 (8) (2006) 1527–1537.
[131] E. Zamora, J. Lupon, J. Vila, A. Urrutia, M. de Antonio, H. Sanz, et al., Estimated glo-
merular ﬁltration rate and prognosis in heart failure: value of the Modiﬁcation of
Diet in Renal Disease Study-4, chronic kidney disease epidemiology collaboration,
and cockroft-gault formulas, J. Am. Coll. Cardiol. 59 (19) (2012) 1709–1715.
[132] B.R. Celli, W. MacNee, Standards for the diagnosis and treatment of patients with
COPD: a summary of the ATS/ERS position paper, Eur. Respir. J. 23 (6) (2004)
932–946.
[133] A.M. Gerdes, G. Iervasi, Thyroid replacement therapy and heart failure, Circulation
122 (4) (2010) 385–393.
[134] S. Sharma, P. Mather, J.T. Eﬁrd, D. Kahn, M. Cheema, S. Rubin, et al.,
Photoplethysmographic signal to screen sleep-disordered breathing in hospital-
ized heart failure patients: feasibility of a prospective clinical pathway, JACC
Heart Fail. 3 (9) (2015) 725–731.
